Source: StreetInsider

Press Release: Meridian Bioscience : Meridian Bioscience Announces Preliminary First Quarter 2019 Revenue; First Quarter 2019 Financial Results Conference Call to be Held on January 24, 2019

Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced that it expects first quarter 2019 revenue to be approximately $51.0 million to $51.5 million compared to $52.3 million in the first quarter of 2018. The year-over-year decline of approximately 2% is being driven by weakness in the Diagnostics segment. The Life Science segment is expected to post revenue about in line with first quarter 2018.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Meridian Bioscience's latest SEC filings

Annual Revenue

Based on data from Meridian Bioscience's latest SEC filings

Employees

John P. Kenny's photo - CEO of Meridian Bioscience

CEO

John P. Kenny

CEO Approval Rating

68/100

Meridian is a life science company that manufactures and distributes diagnostic test kits, rare reagents, specialty biol... Read more